Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03508921 · ClinicalTrials.gov registry record · Phase 4
Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT03508921 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT03508921, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
Injection of OnabotulinumtoxinA (BTX-A) into the bladder is a widely used treatment option for patients with overactive bladder who have failed medical therapy. Urinary tract infection is the most common side effect of this procedure and therefore antibiotics are given around the time of injection in order to prevent these events. While antibiotics are commonly given at the time of injection, the duration of these antibiotic regimens are variable. The investigators propose a study to investigate different antibiotic protocols and their affect on the rate of urinary tract infection after injection.
Interventions
- DRUG Periprocedural Antibiotics
- DRUG Extended Antibiotics
- PROCEDURE Injection of OnabotulinumtoxinA (BTX-A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2022-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03508921
The ClinicalTrials.gov registry entry for NCT03508921 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Periprocedural Antibiotics is the first listed.
NCT03508921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03508921 about?
NCT03508921 is a clinical study titled "Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection". Injection of OnabotulinumtoxinA (BTX-A) into the bladder is a widely used treatment option for patients with overactive bladder who have failed medical therapy. Urinary tract infection is the most common side effect of this procedure and therefore antibiotics are given around the time of injection i...
What is the current status of trial NCT03508921?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2018-07-01. Estimated completion is 2022-06-01.
What interventions are being tested in trial NCT03508921?
The interventions under investigation include: Periprocedural Antibiotics (DRUG), Extended Antibiotics (DRUG), Injection of OnabotulinumtoxinA (BTX-A) (PROCEDURE).
Who is sponsoring clinical trial NCT03508921?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.